The SAnDMAN study Sedation, Analgesia and Delirium MANagement
SANDMAN is an observational study that will describe sedation, analgesia, and delirium strategies used in ICUs around the world.
The study is endorsed by the ESICM Health Services Research & Outcome (HSRO), Neuro-Intensive Care (NIC) and Peri-Operative Intensive Care (POIC) sections.
SAnDMAN received an ESICM 2018 trials group award.
Pain and sedation management has a significant impact on short-term and long-term outcomes of critically ill patients. Despite strong evidence and international guidelines, there is tremendous variability in management internationally. It is vital to understand current practices around the world, however there are no large-scale multinational data describing sedation, analgesia and delirium practices in the intensive care unit (ICU).
Design: Retrospective study to describe patterns of sedative, analgesic, and antipsychotic drug use and adherence to evidence-based strategies and guidelines. We will collect data in upper and lower/middle income countries, academic and non-academic ICUs, and on heterogeneous populations of critically ill patients.
Sample Size: We aim to recruit more than 2000 patients internationally from a minimum of 100 ICUs representing geographic and socio-economic diversity.
SAnDMAN will start enrolling patients beginning 2020.
What data is required?
Inclusion criteria: Data will be collected for a 7-day period (labelled study days 1-7) selected by the site investigator. The investigator will include the last 20 consecutive patients, per centre, who are admitted to ICU and mechanically ventilated in the 3 months before the study start date. For these patients, data collection will start on the day of initiation of mechanical ventilation.
Data Collection: Baseline patient demographic data will be collected on the day 1 of mechanical ventilation. Thereafter, data on sedation, analgesia, delirium, and physical restraint will be collected daily until discharge or death. Data entry will be facilitated by an electronic Case Report Form (eCRF). No patient identifying information will be collected.
Do I need IRB approval?
Ethics committee and appropriate local regulatory approvals must be obtained by each National Coordinator (NC) /Principle Investigator (PI). As SAnDMAN is a retrospective no-risk study, a waived informed consent model will be used.
How is the data that is collected managed?
All data is anonymised and cannot be linked to individual subjects. The data will be stored securely and all procedures regarding data management will comply with EU directive on data protection 95/46/EC.
Who owns and can access the collected data?
Each site investigator is responsible for their own data, and may request an export of their locally collected data after the SAnDMAN database is locked. The request should be addressed to the Principal Investigators.
After the primary SAnDMAN manuscript is published, investigators may publish their local data.
Is there any financial compensation?
There is no financial compensation for participation. Participation in the trial is completely voluntary.
How do I participate?
Please register through the ESICM trials group platform here, or e-mail one of the principle investigators or steering committee members.
SAnDMAN Executive Committee Members
SAnDMAN Steering Committee Members
Geert Meyfroidt MD, Giuseppe Citerio MD, Dylan deLange MD, Ib Jammer MD, Fabio Silvio Taccone, MD Björn Weiss MD, Jorge Salluh MD
Any further Questions?
You can contact the ESICM office: Guy FRANCOIS / Sherihane BENSEMMANE – email@example.com